6533b858fe1ef96bd12b6373

RESEARCH PRODUCT

Topical estrogens and non-hormonal preparations for postmenopausal vulvovaginal atrophy: An EMAS clinical guide

Fatih DurmusogluMick Van TrotsenburgIrene LambrinoudakiDimitrios G. GoulisAntonio CanoPatrice LopesJohannes BitzerAmos PinesIuliana CeausuMargaret ReesPeter ChedrauiLudwig KieselAngelica Lindén HirschbergRisto Erkkola

subject

Non-Hormonal Preparationsmedicine.medical_specialtyChronic conditionmedicine.drug_classmedicine.medical_treatmentUrinary systemVaginal DiseasesUrinary incontinenceVulvovaginal atrophyGeneral Biochemistry Genetics and Molecular BiologyVulvovaginal Atrophy03 medical and health sciences0302 clinical medicineQuality of lifeInternal medicinemedicineHumansEndocrine system030212 general & internal medicineExpert Testimony030219 obstetrics & reproductive medicinebusiness.industryObstetrics and GynecologyEstrogensPostmenopauseTopical EstrogensAdministration IntravaginalEstrogenPractice Guidelines as TopicQuality of LifeFemaleVulvar DiseasesAtrophymedicine.symptombusinessAdjuvant

description

Introduction: Vulvovaginal atrophy (VVA) is a chronic condition caused by estrogen deficiency. It affects around 50% of postmenopausal women, reducing their general and sexual quality of life as well as the quality of their personal relationships. Aim: The aim of this clinical guide is to set out an individualized approach to the management of VVA with topical estrogens and non-hormonal preparations. Materials and methods: Literature review and consensus of expert opinion. Summary recommendations: An individualized approach is required for the management of VVA. Topical low-dose estrogens are effective and also alleviate urinary incontinence and prevent recurrent urinary tract infections. Women should not be denied long-term use of topical estrogens as long as they feel that this treatment is of benefit to them, because the safety data are reassuring. Non-hormonal preparations (lubricants and moisturizers) should be the first-line treatment for VVA in women taking adjuvant endocrine therapies for cancers considered to be hormone-dependent. They can be used over the long term. Sistema de Investigacion y Desarrollo (SINDE) ; Vice-Rectorado de Investigacion & Postgrado (VRIP) of the Universidad Catolica de Santiago de Guayaquil, Guayaquil, Ecuador

yearjournalcountryeditionlanguage
2021-06-01Maturitas
https://doi.org/10.1016/j.maturitas.2021.04.005